Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
NCT07363577
This study is recruiting at 13 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a Phase 3, randomized, double blind, placebo controlled, fixed dose, study designed to evaluate the efficacy, safety, tolerability, and of LB-102 versus placebo for the treatment of adult patients with an acute exacerbation of schizophrenia.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Schizophrenia
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- LB Pharmaceuticals Inc.
- Last updated on ClinicalTrials.gov
- July 27, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arkansas · 3
- Pillar Clinical Research · Bentonville, AR
- Pillar Clinical Research · Little Rock, AR
- Woodland International Research Group · Little Rock, AR
California · 4
- ProScience Research Group · Culver City, CA
- CenExel · Garden Grove, CA
- Synergy San Diego · Lemon Grove, CA
- Clinical Innovations, Inc. · Riverside, CA
Florida · 2
- Health Synergy Clinical Research · Boynton Beach, FL
- Innovative Clinical Research · Miami Lakes, FL
Georgia · 1
- Accelerated Clinical Trial · Snellville, GA
Illinois · 1
- Pillar Clinical Research · Chicago, IL
Missouri · 1
- Arch Clinical Trials · St Louis, MO
Ohio · 1
- Neuro-Behavioral Clinical Research · North Canton, OH
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.